Paper2891981
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
Yarchoan R and 9 others. Lancet, 1988. Cited by 500 papers, by iCite.
Cite this record
ConductScience Library. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Papers, record 2891981. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2891981
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| AIDS-Related Complex | Major topic |
| Acquired Immunodeficiency Syndrome | Major topic |
| Deoxycytidine | Major topic |
| Thymidine | Major topic |
| Adult | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| HIV | |
| Humans | |
| Male | |
| Middle Aged | |
| Zalcitabine | |
| Zidovudine |
Source PubMed
Cited by92
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 500 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41480619 | HIV-associated sensory neuropathy: current progress and future challenges. | NeuroImmune Pharm Ther | 2025 | https://conductscience.org/library/papers/41480619 | PubMed |
| 39697248 | Microwave-assisted synthesis of base-modified fluorescent 1,4-dihydropyridine nucleosides: photophysical characterization and insights. | RSC Adv | 2024 | https://conductscience.org/library/papers/39697248 | PubMed |
| 34728865 | Broad spectrum antiviral nucleosides-Our best hope for the future. | Annu Rep Med Chem | 2021 | https://conductscience.org/library/papers/34728865 | PubMed |
| 32484065 | Chronic pain in people with HIV: a common comorbidity and threat to quality of life. | Pain Manag | 2020 | https://conductscience.org/library/papers/32484065 | PubMed |
| 28631231 | 2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. | Neurochem Res | 2017 | https://conductscience.org/library/papers/28631231 | PubMed |
| 22367397 | HIV-associated sensory neuropathy: risk factors and genetics. | Curr Pain Headache Rep | 2012 | https://conductscience.org/library/papers/22367397 | PubMed |
| 21642979 | Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex. | Nat Med | 2011 | https://conductscience.org/library/papers/21642979 | PubMed |
| 21343462 | Combinatorial approaches to the prevention and treatment of HIV-1 infection. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21343462 | PubMed |
| 21203440 | Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. | PLoS One | 2010 | https://conductscience.org/library/papers/21203440 | PubMed |
| 20018391 | The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. | Antiviral Res | 2010 | https://conductscience.org/library/papers/20018391 | PubMed |
| 19108271 | Poster communications. | Br J Pharmacol | 1993 | https://conductscience.org/library/papers/19108271 | PubMed |
| 11120956 | Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11120956 | PubMed |
| 9880091 | Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. | Drug Saf | 1998 | https://conductscience.org/library/papers/9880091 | PubMed |
| 9527795 | Zalcitabine population pharmacokinetics: application of radioimmunoassay. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9527795 | PubMed |
| 9449274 | Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9449274 | PubMed |
| 9371357 | Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9371357 | PubMed |
| 9342503 | Clinical pharmacokinetics of stavudine. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9342503 | PubMed |
| 9333028 | In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9333028 | PubMed |
| 9032338 | In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. | J Virol | 1997 | https://conductscience.org/library/papers/9032338 | PubMed |
| 8918068 | Effects of incarceration on HIV-infected individuals. | J Natl Med Assoc | 1996 | https://conductscience.org/library/papers/8918068 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2891981
GET https://conductscience.org/api/papers/v1/2891981/cited_by?page=2